Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Text by Ian Fyfe for 'Nature Reviews Neurology'

Molecular pathways involved in early neurodegeneration in progressive multiple sclerosis (MS) have been identified with a novel tissue analysis technique. The work, published in Nature Neuroscience, identifies potential therapeutic targets.

Neurodegeneration underlies progression in MS, but incomplete understanding of the mechanisms involved is hampering development of effective therapies. In their new work, Lars Fugger and colleagues used spatial transcriptomics to gain insight into the specific pathways involved.

'Spatial transcriptomics is a novel technique that can detect the expression of thousands of genes with spatial resolution directly in the tissue,' explains Fugger. 'Thus, it becomes possible to combine the structural detail of microscopy with high-dimensional measurements to capture complex disease pathways.'

The researchers studied post-mortem tissue from 13 patients with progressive MS and five controls. They first mapped areas of neurodegeneration in the grey matter and identified regions at different stages of degeneration. They then analysed changes in gene and protein expression in these areas to determine which molecular pathways are associated with different stages.

'By measuring gene expression and localization in the tissue simultaneously, we were able to identify receptor–ligand pairs in close proximity to one another in specific stages of MS neurodegeneration in the brain, suggesting that the corresponding signalling could be involved in the disease,' explains Fugger.

Crucially, the approach identified pathways involved in early neurodegeneration, when treatment is most likely to be beneficial. These pathways, therefore, represent candidates for therapeutic targeting.

Read the full paper in Nature Neuroscience.

Similar stories

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Visit from the Sir Jules Thorn Charitable Trust

Earlier this month, we were delighted to welcome the Director of the Sir Jules Thorn Charitable Trust, Richard Benson, and its Chair of Trustees, Liz Charal.

Oxford receives £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. Our department will play a major role.